Literature DB >> 17489850

Newborn screening for mucopolysaccharidoses: opinions of patients and their families.

I M Hayes1, V Collins, M Sahhar, J E Wraith, M B Delatycki.   

Abstract

We have conducted a study to assess the opinions of parents of individuals with mucopolysaccharidoses (MPS) and adults with MPS regarding newborn screening (NBS) for this condition, as testing is now technically possible. A questionnaire including a number of hypothetical clinical scenarios about NBS for MPS was distributed to members of MPS support groups from United States and Australia. Questionnaires were returned by 249 members of the US (40% response) and Australian (38% response) support groups. Eleven respondents were adults with MPS and the rest were parents of individuals with MPS. Eighty-six percent of respondents indicated that they would have wanted NBS for their own children. Ninety-seven percent supported the use of NBS for MPS in situations where early treatment that favorably impacts on disease outcome is available, 87% supported NBS when a severe form of MPS was diagnosed, but no treatment is available that improves the long-term outcome and 84% supported NBS for mild MPS where no disease-modifying treatment is available. The most common reason cited in support of NBS was that NBS could avoid a delay in diagnosis and the accompanying distress that delayed diagnosis created. This study has identified strong support for the introduction of NBS for MPS from this group. Psychosocial benefits of screening may outweigh potential harms.

Entities:  

Mesh:

Year:  2007        PMID: 17489850     DOI: 10.1111/j.1399-0004.2007.00783.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

1.  Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers.

Authors:  Emily C Lisi; Shawn E McCandless
Journal:  J Genet Couns       Date:  2015-08-29       Impact factor: 2.537

2.  Enzyme replacement therapy and extended newborn screening for mucopolysaccharidoses: opinions of treating physicians.

Authors:  David J Coman; Ian M Hayes; Veronica Collins; Margaret Sahhar; J Ed Wraith; Martin B Delatycki
Journal:  JIMD Rep       Date:  2011-06-22

3.  Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.

Authors:  Dolan Sondhi; Daniel A Peterson; Andrew M Edelstein; Katrina del Fierro; Neil R Hackett; Ronald G Crystal
Journal:  Exp Neurol       Date:  2008-04-30       Impact factor: 5.330

4.  Expectations and values about expanded newborn screening: a public engagement study.

Authors:  Robin Z Hayeems; Fiona A Miller; Yvonne Bombard; Denise Avard; June Carroll; Brenda Wilson; Julian Little; Pranesh Chakraborty; Jessica Bytautas; Yves Giguere; Judith Allanson; Renata Axler
Journal:  Health Expect       Date:  2013-02-01       Impact factor: 3.377

5.  Patient and family experiences and opinions on adding 22q11 deletion syndrome to the newborn screen.

Authors:  Abigail M Bales; Christina A Zaleski; Elizabeth W McPherson
Journal:  J Genet Couns       Date:  2010-05-22       Impact factor: 2.537

6.  Caregiver opinions about fragile X population screening.

Authors:  Donald B Bailey; Ellen Bishop; Melissa Raspa; Debra Skinner
Journal:  Genet Med       Date:  2011-09-13       Impact factor: 8.822

Review 7.  Perinatal gene transfer to the liver.

Authors:  Tristan R McKay; Ahad A Rahim; Suzanne M K Buckley; Natalie J Ward; Jerry K Y Chan; Steven J Howe; Simon N Waddington
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 8.  Newborn screening in mucopolysaccharidoses.

Authors:  Maria Alice Donati; Elisabetta Pasquini; Marco Spada; Giulia Polo; Alberto Burlina
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

9.  Newborn screening for spinal muscular atrophy: The views of affected families and adults.

Authors:  Felicity K Boardman; Philip J Young; Frances E Griffiths
Journal:  Am J Med Genet A       Date:  2017-04-04       Impact factor: 2.802

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.